Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Collagen Nutraceuticals files for Worldwide Patent Protection on HA Extraction Process and Biofermentation Source
announces the filing of worldwide patent protection for their rooster and hen’s comb HA extraction process and biofermentation method, utlizied in manufacturing PureHA(TM).
- Collagen Nutraceuticals files for Worldwide Patent Protection on HA Extraction Process and Biofermentation Source
announces the filing of worldwide patent protection for their rooster and hen’s comb HA extraction process and biofermentation method, utlizied in manufacturing PureHA(TM).
- Collagen Nutraceuticals files for Worldwide Patent Protection on HA Extraction Process and Biofermentation Source
announces the filing of worldwide patent protection for their rooster and hen’s comb HA extraction process and biofermentation method, utlizied in manufacturing PureHA(TM).
- Collagen Nutraceuticals files for Worldwide Patent Protection on HA Extraction Process and Biofermentation Source
announces the filing of worldwide patent protection for their rooster and hen’s comb HA extraction process and biofermentation method, utlizied in manufacturing PureHA(TM).
- Patent Issued for SLIMALUMA
Company has been awarded US Patent No. 7,060,308 for "Caralluma Extract Products and Processes for Making the same."
- Patent Issued for SLIMALUMA
Company has been awarded US Patent No. 7,060,308 for "Caralluma Extract Products and Processes for Making the same."
- Patent Issued for SLIMALUMA
Company has been awarded US Patent No. 7,060,308 for "Caralluma Extract Products and Processes for Making the same."
- Patent Issued for SLIMALUMA
Company has been awarded US Patent No. 7,060,308 for "Caralluma Extract Products and Processes for Making the same."
- Global Pharmatech Announces a Patent Granted on Its Jutai Soft Capsule Product
Company announces it has been granted an invention patent (ZL03119221.1) on its Jutai soft capsules product containing American Ginseng and Echinacea, with patent protection over the methods of product preparation, utility as well as methods of quality control.
- Global Pharmatech Announces a Patent Granted on Its Jutai Soft Capsule Product
Company announces it has been granted an invention patent (ZL03119221.1) on its Jutai soft capsules product containing American Ginseng and Echinacea, with patent protection over the methods of product preparation, utility as well as methods of quality control.
- Global Pharmatech Announces a Patent Granted on Its Jutai Soft Capsule Product
Company announces it has been granted an invention patent (ZL03119221.1) on its Jutai soft capsules product containing American Ginseng and Echinacea, with patent protection over the methods of product preparation, utility as well as methods of quality control.
- Global Pharmatech Announces a Patent Granted on Its Jutai Soft Capsule Product
Company announces it has been granted an invention patent (ZL03119221.1) on its Jutai soft capsules product containing American Ginseng and Echinacea, with patent protection over the methods of product preparation, utility as well as methods of quality control.
- Global Pharmatech Announces a Patent Granted on Its Jutai Soft Capsule Product
Company announces it has been granted an invention patent (ZL03119221.1) on its Jutai soft capsules product containing American Ginseng and Echinacea, with patent protection over the methods of product preparation, utility as well as methods of quality control.
- NutraCea Continues to Expand Its International Patent Portfolio
Company announces today that its Mexican Patent Application entitled "Supportive Therapy for Diabetes, Hyperglycemia and Hypoglycemia" has been allowed by the Mexican Industrial Property Office with patent number 232655.
- NutraCea Continues to Expand Its International Patent Portfolio
Company announces today that its Mexican Patent Application entitled "Supportive Therapy for Diabetes, Hyperglycemia and Hypoglycemia" has been allowed by the Mexican Industrial Property Office with patent number 232655.
- NutraCea Continues to Expand Its International Patent Portfolio
Company announces today that its Mexican Patent Application entitled "Supportive Therapy for Diabetes, Hyperglycemia and Hypoglycemia" has been allowed by the Mexican Industrial Property Office with patent number 232655.
- Austrian Court Upholds Novogen Patent for Red Clover Isoflavones
Vienna Commercial Court has found that Novogen's (NVGN) isoflavone invention and patent is novel and inventive, and found APOtrend's menopause product Vitalady infringed Novogen's patent and the provisional injunction against Vitalady has been upheld.
- Austrian Court Upholds Novogen Patent for Red Clover Isoflavones
Vienna Commercial Court has found that Novogen's (NVGN) isoflavone invention and patent is novel and inventive, and found APOtrend's menopause product Vitalady infringed Novogen's patent and the provisional injunction against Vitalady has been upheld.
- Austrian Court Upholds Novogen Patent for Red Clover Isoflavones
Vienna Commercial Court has found that Novogen's (NVGN) isoflavone invention and patent is novel and inventive, and found APOtrend's menopause product Vitalady infringed Novogen's patent and the provisional injunction against Vitalady has been upheld.
- Nutrition Formulators, Inc. Completes Its First Generation of Fast Dissolving Supplements
Company has developed an innovative line of fast dissolving tablets for dietary supplements.
- Nutrition Formulators, Inc. Completes Its First Generation of Fast Dissolving Supplements
Company has developed an innovative line of fast dissolving tablets for dietary supplements.
- Nutrition Formulators, Inc. Completes Its First Generation of Fast Dissolving Supplements
Company has developed an innovative line of fast dissolving tablets for dietary supplements.
- Nutrition Formulators, Inc. Completes Its First Generation of Fast Dissolving Supplements
Company has developed an innovative line of fast dissolving tablets for dietary supplements.
- Nutrition Formulators, Inc. Completes Its First Generation of Fast Dissolving Supplements
Company has developed an innovative line of fast dissolving tablets for dietary supplements.
- Nutrition Formulators, Inc. Completes Its First Generation of Fast Dissolving Supplements
Company has developed an innovative line of fast dissolving tablets for dietary supplements.
- Nutrition Formulators, Inc. Completes Its First Generation of Fast Dissolving Supplements
Company has developed an innovative line of fast dissolving tablets for dietary supplements.
- Martek Announces New Infant Formula Licensee
Company announces that South Korean infant formula market leader, Namyang Dairy Products Co., Ltd., has signed a license and supply agreement for rights to use Martek's docosahexaenoic acid (DHA) and arachidonic acid (ARA) in infant formula sold in South Korea.
- Martek Announces New Infant Formula Licensee
Company announces that South Korean infant formula market leader, Namyang Dairy Products Co., Ltd., has signed a license and supply agreement for rights to use Martek's docosahexaenoic acid (DHA) and arachidonic acid (ARA) in infant formula sold in South Korea.
- Martek Announces New Infant Formula Licensee
Company announces that South Korean infant formula market leader, Namyang Dairy Products Co., Ltd., has signed a license and supply agreement for rights to use Martek's docosahexaenoic acid (DHA) and arachidonic acid (ARA) in infant formula sold in South Korea.
- Bayer Pharma Signs Agreement with Vitiva
Bayer Pharma, Slovenia and Vitiva, Slovenia announced today a new broad technology collaboration, based on exclusive isolation of esters from marigold flower, with Bayer Pharma has registering a patent for a natural OTC product worldwide based on marigold flower extracts.
- Bayer Pharma Signs Agreement with Vitiva
Bayer Pharma, Slovenia and Vitiva, Slovenia announced today a new broad technology collaboration, based on exclusive isolation of esters from marigold flower, with Bayer Pharma has registering a patent for a natural OTC product worldwide based on marigold flower extracts.
- Bayer Pharma Signs Agreement with Vitiva
Bayer Pharma, Slovenia and Vitiva, Slovenia announced today a new broad technology collaboration, based on exclusive isolation of esters from marigold flower, with Bayer Pharma has registering a patent for a natural OTC product worldwide based on marigold flower extracts.
- Bayer Pharma Signs Agreement with Vitiva
Bayer Pharma, Slovenia and Vitiva, Slovenia announced today a new broad technology collaboration, based on exclusive isolation of esters from marigold flower, with Bayer Pharma has registering a patent for a natural OTC product worldwide based on marigold flower extracts.
- Bayer Pharma Signs Agreement with Vitiva
Bayer Pharma, Slovenia and Vitiva, Slovenia announced today a new broad technology collaboration, based on exclusive isolation of esters from marigold flower, with Bayer Pharma has registering a patent for a natural OTC product worldwide based on marigold flower extracts.
- Bayer Pharma Signs Agreement with Vitiva
Bayer Pharma, Slovenia and Vitiva, Slovenia announced today a new broad technology collaboration, based on exclusive isolation of esters from marigold flower, with Bayer Pharma has registering a patent for a natural OTC product worldwide based on marigold flower extracts.
- New Patent Promotes Soy Isoflavone Benefits
The U.S. Patent Office has issued patent number 7,045,155 to Novogen, Ltd; This patent, which Acatris has exclusively licensed, protects compositions for the amelioration of human health conditions that are responsive to treatment with phyto-estrogens. The compositions comprise phytoestrogen-enriched extracts primarily from soy hypocotyls.
- New Patent Promotes Soy Isoflavone Benefits
The U.S. Patent Office has issued patent number 7,045,155 to Novogen, Ltd; This patent, which Acatris has exclusively licensed, protects compositions for the amelioration of human health conditions that are responsive to treatment with phyto-estrogens. The compositions comprise phytoestrogen-enriched extracts primarily from soy hypocotyls.
- New Patent Promotes Soy Isoflavone Benefits
The U.S. Patent Office has issued patent number 7,045,155 to Novogen, Ltd; This patent, which Acatris has exclusively licensed, protects compositions for the amelioration of human health conditions that are responsive to treatment with phyto-estrogens. The compositions comprise phytoestrogen-enriched extracts primarily from soy hypocotyls.
- ReGen Signs First Commercialisation Deal for Colostrinin(TM) with Metagenics
Company has entered into an exclusive licence agreement with Metagenics, Inc. for the commercialisation of ReGen's Colostrinin(TM) as a human nutraceutical in North America.
- ReGen Signs First Commercialisation Deal for Colostrinin(TM) with Metagenics
Company has entered into an exclusive licence agreement with Metagenics, Inc. for the commercialisation of ReGen's Colostrinin(TM) as a human nutraceutical in North America.
- ReGen Signs First Commercialisation Deal for Colostrinin(TM) with Metagenics
Company has entered into an exclusive licence agreement with Metagenics, Inc. for the commercialisation of ReGen's Colostrinin(TM) as a human nutraceutical in North America.
- ReGen Signs First Commercialisation Deal for Colostrinin(TM) with Metagenics
Company has entered into an exclusive licence agreement with Metagenics, Inc. for the commercialisation of ReGen's Colostrinin(TM) as a human nutraceutical in North America.
- ReGen Signs First Commercialisation Deal for Colostrinin(TM) with Metagenics
Company has entered into an exclusive licence agreement with Metagenics, Inc. for the commercialisation of ReGen's Colostrinin(TM) as a human nutraceutical in North America.
- ReGen Signs First Commercialisation Deal for Colostrinin(TM) with Metagenics
Company has entered into an exclusive licence agreement with Metagenics, Inc. for the commercialisation of ReGen's Colostrinin(TM) as a human nutraceutical in North America.
- NZyme Pharmaceuticals(TM), Inc. Unveils New Patent for Subtilisin NAT Applications in Decreasing Blood Viscosity
Company announces a patent pending application for NZyme brand (Subtilisin NAT) for decreasing whole blood viscosity in the central therapeutic role of preventing and treating vascular disease
- NZyme Pharmaceuticals(TM), Inc. Unveils New Patent for Subtilisin NAT Applications in Decreasing Blood Viscosity
Company announces a patent pending application for NZyme brand (Subtilisin NAT) for decreasing whole blood viscosity in the central therapeutic role of preventing and treating vascular disease
- NZyme Pharmaceuticals(TM), Inc. Unveils New Patent for Subtilisin NAT Applications in Decreasing Blood Viscosity
Company announces a patent pending application for NZyme brand (Subtilisin NAT) for decreasing whole blood viscosity in the central therapeutic role of preventing and treating vascular disease
- NZyme Pharmaceuticals(TM), Inc. Unveils New Patent for Subtilisin NAT Applications in Decreasing Blood Viscosity
Company announces a patent pending application for NZyme brand (Subtilisin NAT) for decreasing whole blood viscosity in the central therapeutic role of preventing and treating vascular disease
- NZyme Pharmaceuticals(TM), Inc. Unveils New Patent for Subtilisin NAT Applications in Decreasing Blood Viscosity
Company announces a patent pending application for NZyme brand (Subtilisin NAT) for decreasing whole blood viscosity in the central therapeutic role of preventing and treating vascular disease
- Fuji Chemical Granted Inflammation Patent For Astaxanthin
Fuji Chemical Industry Co., Ltd. has been granted U.S. Patent No. 7,078,040, which involves inhibiting the expression of inflammatory cytokines and chemokines by the administration of astaxnathin.
- Fuji Chemical Granted Inflammation Patent For Astaxanthin
Fuji Chemical Industry Co., Ltd. has been granted U.S. Patent No. 7,078,040, which involves inhibiting the expression of inflammatory cytokines and chemokines by the administration of astaxnathin.
- Fuji Chemical Granted Inflammation Patent For Astaxanthin
Fuji Chemical Industry Co., Ltd. has been granted U.S. Patent No. 7,078,040, which involves inhibiting the expression of inflammatory cytokines and chemokines by the administration of astaxnathin.
- Provexis Announces Exclusivity Agreement
Company has entered into an exclusivity agreement for a period of 12 months with a major global branded food business for the joint development and use of its patented Fruitflow(TM) heart-health technology.
- Provexis Announces Exclusivity Agreement
Company has entered into an exclusivity agreement for a period of 12 months with a major global branded food business for the joint development and use of its patented Fruitflow(TM) heart-health technology.
- Provexis Announces Exclusivity Agreement
Company has entered into an exclusivity agreement for a period of 12 months with a major global branded food business for the joint development and use of its patented Fruitflow(TM) heart-health technology.
- Provexis Announces Exclusivity Agreement
Company has entered into an exclusivity agreement for a period of 12 months with a major global branded food business for the joint development and use of its patented Fruitflow(TM) heart-health technology.
- Provexis Announces Exclusivity Agreement
Company has entered into an exclusivity agreement for a period of 12 months with a major global branded food business for the joint development and use of its patented Fruitflow(TM) heart-health technology.
- Provexis Announces Exclusivity Agreement
Company has entered into an exclusivity agreement for a period of 12 months with a major global branded food business for the joint development and use of its patented Fruitflow(TM) heart-health technology.
- Carotech Enters into Exclusive Arrangement with Metagenics for Tocomin® SupraBio(TM) for the Healthcare Practitioner Market
Company has entered into an exclusive license agreement with Metagenics, Inc. for the commercialization of Tocomin® SupraBio(TM) – a patented, bio-enhanced, natural, full-spectrum palm tocotrienol complex for the healthcare practitioner channel of distribution in North America.
- Carotech Enters into Exclusive Arrangement with Metagenics for Tocomin® SupraBio(TM) for the Healthcare Practitioner Market
Company has entered into an exclusive license agreement with Metagenics, Inc. for the commercialization of Tocomin® SupraBio(TM) – a patented, bio-enhanced, natural, full-spectrum palm tocotrienol complex for the healthcare practitioner channel of distribution in North America.
- Carotech Enters into Exclusive Arrangement with Metagenics for Tocomin® SupraBio(TM) for the Healthcare Practitioner Market
Company has entered into an exclusive license agreement with Metagenics, Inc. for the commercialization of Tocomin® SupraBio(TM) – a patented, bio-enhanced, natural, full-spectrum palm tocotrienol complex for the healthcare practitioner channel of distribution in North America.
- Sabinsa Corporation Granted U.S. Patent for Garcitrin(R) Ingredient
Company has been issued U.S. patent #7,063,861, entitled "Bioavailable Composition of Natural and Synthetic HCA" for the company's Garcitrin(R) ingredient.
- Sabinsa Corporation Granted U.S. Patent for Garcitrin(R) Ingredient
Company has been issued U.S. patent #7,063,861, entitled "Bioavailable Composition of Natural and Synthetic HCA" for the company's Garcitrin(R) ingredient.
- Sabinsa Corporation Granted U.S. Patent for Garcitrin(R) Ingredient
Company has been issued U.S. patent #7,063,861, entitled "Bioavailable Composition of Natural and Synthetic HCA" for the company's Garcitrin(R) ingredient.
- Burcon enters into material transfer agreements Puratein(R) and Supertein(TM) to be tested by food & beverage makers
Company announces that it has entered into material transfer agreements with some of the world's foremost food and beverage companies, enabling the company to provide samples of Burcon's proteins; Puratein(R) and Supertein(TM) to food and beverage companies for testing while protecting certain intellectual property interests of all of the parties involved.
- Burcon enters into material transfer agreements Puratein(R) and Supertein(TM) to be tested by food & beverage makers
Company announces that it has entered into material transfer agreements with some of the world's foremost food and beverage companies, enabling the company to provide samples of Burcon's proteins; Puratein(R) and Supertein(TM) to food and beverage companies for testing while protecting certain intellectual property interests of all of the parties involved.
- Burcon enters into material transfer agreements Puratein(R) and Supertein(TM) to be tested by food & beverage makers
Company announces that it has entered into material transfer agreements with some of the world's foremost food and beverage companies, enabling the company to provide samples of Burcon's proteins; Puratein(R) and Supertein(TM) to food and beverage companies for testing while protecting certain intellectual property interests of all of the parties involved.
- Burcon enters into material transfer agreements Puratein(R) and Supertein(TM) to be tested by food & beverage makers
Company announces that it has entered into material transfer agreements with some of the world's foremost food and beverage companies, enabling the company to provide samples of Burcon's proteins; Puratein(R) and Supertein(TM) to food and beverage companies for testing while protecting certain intellectual property interests of all of the parties involved.
- Nutri Pharmaceuticals Research Inc. Introduces Near Odorless O2P(TM) DHA Available in Both Liquid Oil and Dry Powder Forms
Company has announced the introduction of a near odorless and tasteless DHA oil and companion dry powder.
- Nutri Pharmaceuticals Research Inc. Introduces Near Odorless O2P(TM) DHA Available in Both Liquid Oil and Dry Powder Forms
Company has announced the introduction of a near odorless and tasteless DHA oil and companion dry powder.
- Tate & Lyle Interim Results Announcement 2009
Tate & Lyle has announced their 2009 Interim results, reporting the Group's performance, before the impact of exchange translation, remains on track to meet our expectations for the full year.
- NPI Daily - Top of The News for Nov. 6, 2009 - National Organic Standards Board Votes to Crack Down on Organic Personal Care Cheaters
Nature's Sunshine Products Reports FY09 Q3 Operating Results; SunOpta Announces FY09 Q3 Results; Tate & Lyle Interim Results Announcement 2009; NOW Foods Receives the 2009 Illinois Governor's Sustainability Award; Transport-C Supports Vitamin Angels at SSW; Cantox at Supplyside West; New Support Showing Immunoglobulin Supplementation Enhances Immune System; FDA Warning: Over-the-Counter Sex Enhancement Drug May Cause 'Dangerously' Low Blood Pressure; EPAX AS Achieves 'Friend of the Sea' Certification; National Organic Standards Board Votes to Crack Down on Organic Personal Care Cheaters; Fast-C™ At SupplySide West: US Clinical Trials Data Available In Booth ; Nutty Flavor & Healthy Boost of Omega-3 Make Hemp Seed an Ideal Ingredient; DSM's tensVida® Recognized for Innovative Development; Nutrition 21 Announces Addition of Innovative New Probiotic + Omega-3 Fish Oil Combination Product; Glanbia Nutritionals Offers More Than Ingredients for Nutritional Beverages; Whole Foods Market(R) Offers Natural Solutions to Help Build Up Body Defenses With Immune System Support; Doug Reyes Joins Embria as Regional Sales Manager; Michael F. Hines Joins Board of General Nutrition Centers, Inc.; Dr. Arnold Hirsch Celebrates 50th Anniversary with the American Chemical Society
- NPI Daily - Top of The News for Nov. 6, 2009 - National Organic Standards Board Votes to Crack Down on Organic Personal Care Cheaters
Nature's Sunshine Products Reports FY09 Q3 Operating Results; SunOpta Announces FY09 Q3 Results; Tate & Lyle Interim Results Announcement 2009; NOW Foods Receives the 2009 Illinois Governor's Sustainability Award; Transport-C Supports Vitamin Angels at SSW; Cantox at Supplyside West; New Support Showing Immunoglobulin Supplementation Enhances Immune System; FDA Warning: Over-the-Counter Sex Enhancement Drug May Cause 'Dangerously' Low Blood Pressure; EPAX AS Achieves 'Friend of the Sea' Certification; National Organic Standards Board Votes to Crack Down on Organic Personal Care Cheaters; Fast-C™ At SupplySide West: US Clinical Trials Data Available In Booth ; Nutty Flavor & Healthy Boost of Omega-3 Make Hemp Seed an Ideal Ingredient; DSM's tensVida® Recognized for Innovative Development; Nutrition 21 Announces Addition of Innovative New Probiotic + Omega-3 Fish Oil Combination Product; Glanbia Nutritionals Offers More Than Ingredients for Nutritional Beverages; Whole Foods Market(R) Offers Natural Solutions to Help Build Up Body Defenses With Immune System Support; Doug Reyes Joins Embria as Regional Sales Manager; Michael F. Hines Joins Board of General Nutrition Centers, Inc.; Dr. Arnold Hirsch Celebrates 50th Anniversary with the American Chemical Society
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Carlson Laboratories Receives Better Nutrition Best of Supplements Awards for 2009
Carlson Laboratories has received awards for three of its products in this year's Best of Supplements Awards presented by Better Nutrition Magazine.
- Carlson Laboratories Receives Better Nutrition Best of Supplements Awards for 2009
Carlson Laboratories has received awards for three of its products in this year's Best of Supplements Awards presented by Better Nutrition Magazine.
- Carlson Laboratories Receives Better Nutrition Best of Supplements Awards for 2009
Carlson Laboratories has received awards for three of its products in this year's Best of Supplements Awards presented by Better Nutrition Magazine.
- Carlson Laboratories Receives Better Nutrition Best of Supplements Awards for 2009
Carlson Laboratories has received awards for three of its products in this year's Best of Supplements Awards presented by Better Nutrition Magazine.
- Carlson Laboratories Receives Better Nutrition Best of Supplements Awards for 2009
Carlson Laboratories has received awards for three of its products in this year's Best of Supplements Awards presented by Better Nutrition Magazine.
- Sharp-GPC™ 45F by Enzymotec
Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline.
- Sharp-GPC™ 45F by Enzymotec
Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline.
- Sharp-GPC™ 45F by Enzymotec
Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline.
- Sharp-GPC™ 45F by Enzymotec
Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline.
- Sharp-GPC™ 45F by Enzymotec
Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline.
- Sharp-GPC™ 45F by Enzymotec
Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline.
- Natural Products Foundation Representatives Meet with Federal Regulators on Truth in Advertising Campaign
The Natural Products Foundation recently met with officials from both U.S. Food and Drug Administration and Federal Trade Commission to turn over the names of 10 companies that have continued to make drug or disease claims in their advertising and other promotional materials.
- Natural Products Foundation Representatives Meet with Federal Regulators on Truth in Advertising Campaign
The Natural Products Foundation recently met with officials from both U.S. Food and Drug Administration and Federal Trade Commission to turn over the names of 10 companies that have continued to make drug or disease claims in their advertising and other promotional materials.
- Natural Products Foundation Representatives Meet with Federal Regulators on Truth in Advertising Campaign
The Natural Products Foundation recently met with officials from both U.S. Food and Drug Administration and Federal Trade Commission to turn over the names of 10 companies that have continued to make drug or disease claims in their advertising and other promotional materials.
- Natural Products Foundation Representatives Meet with Federal Regulators on Truth in Advertising Campaign
The Natural Products Foundation recently met with officials from both U.S. Food and Drug Administration and Federal Trade Commission to turn over the names of 10 companies that have continued to make drug or disease claims in their advertising and other promotional materials.
- Natural Products Foundation Representatives Meet with Federal Regulators on Truth in Advertising Campaign
The Natural Products Foundation recently met with officials from both U.S. Food and Drug Administration and Federal Trade Commission to turn over the names of 10 companies that have continued to make drug or disease claims in their advertising and other promotional materials.
- Taming Fear of the H1N1 Flu Vaccine
- Taming Fear of the H1N1 Flu Vaccine
- Natural Cold and Flu Remedies: Do They Help?
- Natural Cold and Flu Remedies: Do They Help?
- Exercise as Pain Therapy
- Exercise as Pain Therapy
|
Requester: Her Majesty the Queen in Right of Canada as represented by the Minister of Agriculture and Agri-Food Canada (“AAFC”)
Available Rights: For the licensed right to produce and market Stevia rebaudiana cultivars, seed and/or product. The nature of the license (i.e. sole or non-exclusive), territory and field of use being sought.
Variety Description: Three Stevia rebaudiana cultivars (GII Bulk, GI Sib and GVII Bulk) with >80% of total glycosides consisting of rebaudioside A and reproduced by seed, which was at AAFC, Southern Crop Protection and Food Research Centre in London, Ontario.
Breeder Seed Availability: 20,000 seeds of each cultivar will be made available on execution of a License.
Proposal: The RFP is comprised of
(1) This Notice of RFP;
(2) Guidelines for Submitting Proposals; and
(3) Variety Description.
The successful respondents to the Request for Proposals (RFP) will be determined by the overall best economic value to Canada as adjudged by the criteria identified in article 10 – Evaluation Criteria of the document entitled “Guidelines for Submitting Proposals”.
AAFC reserves the right to negotiate with any proponent and to modify that proposal without notifying or offering the same terms and conditions to the other proponents. This is not a tender.
AAFC reserves the right to reject any or all proposals.
Deadline: Proposals must be received at the specified address by not later than 4:00 pm DST on Friday, August 11, 2006. If proposals are sent by facsimile to meet this time limit, hard copy originals must be received by 4:00 pm DST on Thursday, August 17, 2006 to be considered. Proposals must be marked “Protected - Business Information”.
Address for
Submissions: Sandy Hushagen
Commercialization Officer
Office of Intellectual Property
Agriculture and Agri-Food Canada
1391 Sandford St.
London, ON N5V 4T3
Contacts: Any inquiries on the RFP process should be directed to:
Sandy Hushagen, Commercialization Officer
Office of Intellectual Property and Commercialization
Agriculture and Agri-Food Canada
1391 Sandford St.
London, ON N5V 4T3
Fax: (519) 457-3997
E-mail: hushagens@agr.gc.ca
Any inquiries for technical information on varieties should be directed to:
Dr. Jim Brandle
Agriculture and Agri-Food Canada
1391 Sandford St.
London, ON N5V 4T3
Fax: (519) 457-3997
E-Mail: brandleje@agr.gc.ca
All inquiries MUST be in writing. All replies shall be made in writing. AAFC shall not be liable for damages suffered by a proponent who acts upon an oral representation or an oral reply from AAFC.
Responses to general inquiries will be made available to all proponents, unless such publication would reveal proprietary information.
AAFC encourages small and medium enterprises (SME's) to submit proposals under this process.
Additional information is posted on NPIcenter's Business Information and Technology Exchange : http://www.npicommunity.com/Exchange/tabid/63/Default.aspx |